Treatment of neuroendocrine tumors associated with carcinoid syndrome

This week's issue of The Lancet investigates everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome.

Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour a